nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycerol Phenylbutyrate—PNLIP—Retinoid metabolism and transport—GPC3—kidney cancer	0.0513	0.174	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Diseases associated with visual transduction—GPC3—kidney cancer	0.0262	0.0887	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Lipid and lipoprotein metabolism—SCARB1—kidney cancer	0.022	0.0746	CbGpPWpGaD
Glycerol Phenylbutyrate—Abdominal pain upper—Pazopanib—kidney cancer	0.012	0.0171	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain upper—Everolimus—kidney cancer	0.00949	0.0135	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Temsirolimus—kidney cancer	0.00841	0.0119	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain upper—Sorafenib—kidney cancer	0.00824	0.0117	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain upper—Sunitinib—kidney cancer	0.00793	0.0113	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Pazopanib—kidney cancer	0.00793	0.0113	CcSEcCtD
Glycerol Phenylbutyrate—Flatulence—Pazopanib—kidney cancer	0.00781	0.0111	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal discomfort—Sorafenib—kidney cancer	0.00747	0.0106	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal discomfort—Sunitinib—kidney cancer	0.00719	0.0102	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.00716	0.0242	CbGpPWpGaD
Glycerol Phenylbutyrate—Nervous system disorder—Temsirolimus—kidney cancer	0.00673	0.00956	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Pazopanib—kidney cancer	0.00634	0.00901	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Everolimus—kidney cancer	0.00626	0.00888	CcSEcCtD
Glycerol Phenylbutyrate—Flatulence—Everolimus—kidney cancer	0.00617	0.00875	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Erlotinib—kidney cancer	0.00604	0.00857	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Temsirolimus—kidney cancer	0.00597	0.00847	CcSEcCtD
Glycerol Phenylbutyrate—Flatulence—Erlotinib—kidney cancer	0.00595	0.00845	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.00593	0.00842	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Temsirolimus—kidney cancer	0.00592	0.0084	CcSEcCtD
Glycerol Phenylbutyrate—Dyspepsia—Pazopanib—kidney cancer	0.00569	0.00808	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Pazopanib—kidney cancer	0.00562	0.00798	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Temsirolimus—kidney cancer	0.00562	0.00797	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Pazopanib—kidney cancer	0.00559	0.00793	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Pazopanib—kidney cancer	0.00558	0.00792	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Sorafenib—kidney cancer	0.00543	0.00771	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Temsirolimus—kidney cancer	0.00543	0.00771	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain upper—Paclitaxel—kidney cancer	0.00533	0.00756	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Pazopanib—kidney cancer	0.00529	0.00751	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Sunitinib—kidney cancer	0.00523	0.00742	CcSEcCtD
Glycerol Phenylbutyrate—Flatulence—Sunitinib—kidney cancer	0.00515	0.00731	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Pazopanib—kidney cancer	0.00511	0.00726	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Everolimus—kidney cancer	0.00501	0.00711	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Temsirolimus—kidney cancer	0.00493	0.00699	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Erlotinib—kidney cancer	0.00483	0.00686	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Temsirolimus—kidney cancer	0.0047	0.00667	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Pazopanib—kidney cancer	0.00464	0.00659	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—ACY1—kidney cancer	0.0046	0.0156	CbGpPWpGaD
Glycerol Phenylbutyrate—Dizziness—Temsirolimus—kidney cancer	0.00454	0.00645	CcSEcCtD
Glycerol Phenylbutyrate—Dyspepsia—Everolimus—kidney cancer	0.0045	0.00638	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Vinblastine—kidney cancer	0.00446	0.00633	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Everolimus—kidney cancer	0.00444	0.0063	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Pazopanib—kidney cancer	0.00443	0.00628	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Everolimus—kidney cancer	0.00441	0.00626	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Everolimus—kidney cancer	0.0044	0.00625	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—CCBL1—kidney cancer	0.00439	0.0149	CbGpPWpGaD
Glycerol Phenylbutyrate—Abdominal pain upper—Capecitabine—kidney cancer	0.00437	0.0062	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Temsirolimus—kidney cancer	0.00437	0.0062	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Sorafenib—kidney cancer	0.00435	0.00617	CcSEcCtD
Glycerol Phenylbutyrate—Dyspepsia—Erlotinib—kidney cancer	0.00434	0.00616	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Temsirolimus—kidney cancer	0.00433	0.00615	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Temsirolimus—kidney cancer	0.00433	0.00614	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Temsirolimus—kidney cancer	0.0043	0.00611	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Erlotinib—kidney cancer	0.00428	0.00608	CcSEcCtD
Glycerol Phenylbutyrate—Dizziness—Pazopanib—kidney cancer	0.00428	0.00607	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00426	0.00604	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Erlotinib—kidney cancer	0.00425	0.00603	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Vinblastine—kidney cancer	0.00419	0.00595	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Sunitinib—kidney cancer	0.00418	0.00594	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Everolimus—kidney cancer	0.00418	0.00593	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Pazopanib—kidney cancer	0.00411	0.00584	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Pazopanib—kidney cancer	0.00408	0.00579	CcSEcCtD
Glycerol Phenylbutyrate—Nausea—Temsirolimus—kidney cancer	0.00408	0.00579	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Pazopanib—kidney cancer	0.00408	0.00578	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Vinblastine—kidney cancer	0.00405	0.00575	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Pazopanib—kidney cancer	0.00405	0.00575	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Everolimus—kidney cancer	0.00404	0.00573	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Erlotinib—kidney cancer	0.00403	0.00572	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—AMER1—kidney cancer	0.00397	0.0134	CbGpPWpGaD
Glycerol Phenylbutyrate—Abdominal discomfort—Capecitabine—kidney cancer	0.00397	0.00563	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.00392	0.0133	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PDHB—kidney cancer	0.00391	0.0132	CbGpPWpGaD
Glycerol Phenylbutyrate—Dyspepsia—Sorafenib—kidney cancer	0.0039	0.00554	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Erlotinib—kidney cancer	0.0039	0.00553	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Sorafenib—kidney cancer	0.00385	0.00547	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—OR4C13—kidney cancer	0.00385	0.013	CbGpPWpGaD
Glycerol Phenylbutyrate—Nausea—Pazopanib—kidney cancer	0.00384	0.00545	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00383	0.00543	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Sorafenib—kidney cancer	0.00382	0.00543	CcSEcCtD
Glycerol Phenylbutyrate—Dyspepsia—Sunitinib—kidney cancer	0.00376	0.00533	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Sunitinib—kidney cancer	0.00371	0.00526	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00368	0.00523	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Vinblastine—kidney cancer	0.00368	0.00522	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—CCBL1—kidney cancer	0.00368	0.0124	CbGpPWpGaD
Glycerol Phenylbutyrate—Fatigue—Sunitinib—kidney cancer	0.00368	0.00522	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Everolimus—kidney cancer	0.00366	0.0052	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Sorafenib—kidney cancer	0.00363	0.00515	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Vincristine—kidney cancer	0.00354	0.00502	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Erlotinib—kidney cancer	0.00354	0.00502	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Paclitaxel—kidney cancer	0.00351	0.00499	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Dactinomycin—kidney cancer	0.00351	0.00498	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Vinblastine—kidney cancer	0.00351	0.00498	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Sorafenib—kidney cancer	0.00351	0.00498	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Everolimus—kidney cancer	0.00349	0.00496	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Sunitinib—kidney cancer	0.00349	0.00495	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Dactinomycin—kidney cancer	0.00348	0.00494	CcSEcCtD
Glycerol Phenylbutyrate—Flatulence—Paclitaxel—kidney cancer	0.00346	0.00491	CcSEcCtD
Glycerol Phenylbutyrate—Dizziness—Vinblastine—kidney cancer	0.00339	0.00481	CcSEcCtD
Glycerol Phenylbutyrate—Dizziness—Everolimus—kidney cancer	0.00338	0.00479	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Sunitinib—kidney cancer	0.00337	0.00479	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Erlotinib—kidney cancer	0.00337	0.00479	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Gemcitabine—kidney cancer	0.00336	0.00477	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—GPC3—kidney cancer	0.00333	0.0113	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.00333	0.0113	CbGpPWpGaD
Glycerol Phenylbutyrate—Gastrointestinal pain—Dactinomycin—kidney cancer	0.0033	0.00469	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—LATS1—kidney cancer	0.00327	0.0111	CbGpPWpGaD
Glycerol Phenylbutyrate—Vomiting—Vinblastine—kidney cancer	0.00326	0.00463	CcSEcCtD
Glycerol Phenylbutyrate—Dizziness—Erlotinib—kidney cancer	0.00326	0.00463	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Everolimus—kidney cancer	0.00325	0.00461	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Everolimus—kidney cancer	0.00322	0.00457	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Everolimus—kidney cancer	0.00322	0.00457	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Vinblastine—kidney cancer	0.00321	0.00456	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Everolimus—kidney cancer	0.0032	0.00454	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Dactinomycin—kidney cancer	0.00319	0.00453	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PPAT—kidney cancer	0.00319	0.0108	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—GLIPR1—kidney cancer	0.00319	0.0108	CbGpPWpGaD
Glycerol Phenylbutyrate—Asthenia—Sorafenib—kidney cancer	0.00318	0.00452	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	0.00315	0.0107	CbGpPWpGaD
Glycerol Phenylbutyrate—Decreased appetite—Vincristine—kidney cancer	0.00314	0.00445	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Erlotinib—kidney cancer	0.00313	0.00445	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.00312	0.0105	CbGpPWpGaD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Vincristine—kidney cancer	0.00312	0.00442	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Vincristine—kidney cancer	0.00311	0.00442	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Erlotinib—kidney cancer	0.00311	0.00441	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Erlotinib—kidney cancer	0.0031	0.00441	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Erlotinib—kidney cancer	0.00309	0.00438	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—ST3GAL2—kidney cancer	0.00308	0.0104	CbGpPWpGaD
Glycerol Phenylbutyrate—Asthenia—Sunitinib—kidney cancer	0.00306	0.00435	CcSEcCtD
Glycerol Phenylbutyrate—Nausea—Vinblastine—kidney cancer	0.00305	0.00432	CcSEcCtD
Glycerol Phenylbutyrate—Nausea—Everolimus—kidney cancer	0.00303	0.00431	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Sorafenib—kidney cancer	0.00303	0.00431	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Gemcitabine—kidney cancer	0.00298	0.00422	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—FH—kidney cancer	0.00297	0.01	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—APRT—kidney cancer	0.00297	0.01	CbGpPWpGaD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00296	0.0042	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Gemcitabine—kidney cancer	0.00295	0.00419	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal pain—Vincristine—kidney cancer	0.00295	0.00419	CcSEcCtD
Glycerol Phenylbutyrate—Dizziness—Sorafenib—kidney cancer	0.00293	0.00416	CcSEcCtD
Glycerol Phenylbutyrate—Nausea—Erlotinib—kidney cancer	0.00293	0.00416	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Sunitinib—kidney cancer	0.00292	0.00414	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.0029	0.00981	CbGpPWpGaD
Glycerol Phenylbutyrate—Asthenia—Dactinomycin—kidney cancer	0.0029	0.00411	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—SLC5A3—kidney cancer	0.00289	0.00977	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—PGK1—kidney cancer	0.00289	0.00977	CbGpPWpGaD
Glycerol Phenylbutyrate—Malnutrition—Capecitabine—kidney cancer	0.00288	0.00409	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Vincristine—kidney cancer	0.00285	0.00405	CcSEcCtD
Glycerol Phenylbutyrate—Flatulence—Capecitabine—kidney cancer	0.00284	0.00403	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—LDHB—kidney cancer	0.00283	0.00958	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—SFRP2—kidney cancer	0.00283	0.00958	CbGpPWpGaD
Glycerol Phenylbutyrate—Dizziness—Sunitinib—kidney cancer	0.00282	0.004	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Sorafenib—kidney cancer	0.00282	0.004	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain upper—Doxorubicin—kidney cancer	0.00282	0.004	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Paclitaxel—kidney cancer	0.00281	0.00399	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Sorafenib—kidney cancer	0.0028	0.00397	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Sorafenib—kidney cancer	0.00279	0.00396	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—GPC3—kidney cancer	0.00279	0.00943	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—AMER1—kidney cancer	0.00278	0.00941	CbGpPWpGaD
Glycerol Phenylbutyrate—Headache—Sorafenib—kidney cancer	0.00278	0.00394	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Dactinomycin—kidney cancer	0.00276	0.00392	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Sunitinib—kidney cancer	0.00271	0.00385	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—CA2—kidney cancer	0.00271	0.00918	CbGpPWpGaD
Glycerol Phenylbutyrate—Rash—Sunitinib—kidney cancer	0.00269	0.00382	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Sunitinib—kidney cancer	0.00269	0.00382	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Sunitinib—kidney cancer	0.00267	0.00379	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—ALAD—kidney cancer	0.00264	0.00894	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—TCEB1—kidney cancer	0.00264	0.00893	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—TCEB2—kidney cancer	0.00264	0.00893	CbGpPWpGaD
Glycerol Phenylbutyrate—Nausea—Sorafenib—kidney cancer	0.00263	0.00374	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Vincristine—kidney cancer	0.00259	0.00368	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—ST3GAL2—kidney cancer	0.00258	0.00873	CbGpPWpGaD
Glycerol Phenylbutyrate—Vomiting—Dactinomycin—kidney cancer	0.00257	0.00365	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Dactinomycin—kidney cancer	0.00255	0.00362	CcSEcCtD
Glycerol Phenylbutyrate—Nausea—Sunitinib—kidney cancer	0.00253	0.0036	CcSEcCtD
Glycerol Phenylbutyrate—Dyspepsia—Paclitaxel—kidney cancer	0.00252	0.00358	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—ALDH1A1—kidney cancer	0.00252	0.00853	CbGpPWpGaD
Glycerol Phenylbutyrate—Decreased appetite—Paclitaxel—kidney cancer	0.00249	0.00354	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00247	0.00351	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Paclitaxel—kidney cancer	0.00247	0.00351	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Vincristine—kidney cancer	0.00247	0.0035	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Gemcitabine—kidney cancer	0.00246	0.00349	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—SLC5A3—kidney cancer	0.00242	0.00818	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PGK1—kidney cancer	0.00242	0.00818	CbGpPWpGaD
Glycerol Phenylbutyrate—Nausea—Dactinomycin—kidney cancer	0.0024	0.00341	CcSEcCtD
Glycerol Phenylbutyrate—Dizziness—Vincristine—kidney cancer	0.00239	0.00339	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—LDHB—kidney cancer	0.00237	0.00802	CbGpPWpGaD
Glycerol Phenylbutyrate—Gastrointestinal pain—Paclitaxel—kidney cancer	0.00234	0.00333	CcSEcCtD
Glycerol Phenylbutyrate—Diarrhoea—Gemcitabine—kidney cancer	0.00234	0.00332	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—GPC3—kidney cancer	0.00233	0.00789	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—CER1—kidney cancer	0.00233	0.00789	CbGpPWpGaD
Glycerol Phenylbutyrate—Nervous system disorder—Capecitabine—kidney cancer	0.00231	0.00327	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Vincristine—kidney cancer	0.00229	0.00326	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Vincristine—kidney cancer	0.00228	0.00323	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Vincristine—kidney cancer	0.00227	0.00323	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Paclitaxel—kidney cancer	0.00227	0.00322	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Vincristine—kidney cancer	0.00226	0.00321	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Gemcitabine—kidney cancer	0.00218	0.00309	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Gemcitabine—kidney cancer	0.00216	0.00306	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Gemcitabine—kidney cancer	0.00216	0.00306	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—RPL14—kidney cancer	0.00215	0.00726	CbGpPWpGaD
Glycerol Phenylbutyrate—Headache—Gemcitabine—kidney cancer	0.00214	0.00304	CcSEcCtD
Glycerol Phenylbutyrate—Nausea—Vincristine—kidney cancer	0.00214	0.00304	CcSEcCtD
Glycerol Phenylbutyrate—Dyspepsia—Capecitabine—kidney cancer	0.00207	0.00294	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Paclitaxel—kidney cancer	0.00206	0.00292	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—CA9—kidney cancer	0.00206	0.00696	CbGpPWpGaD
Glycerol Phenylbutyrate—Decreased appetite—Capecitabine—kidney cancer	0.00204	0.0029	CcSEcCtD
Glycerol Phenylbutyrate—Nausea—Gemcitabine—kidney cancer	0.00203	0.00289	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00203	0.00288	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Capecitabine—kidney cancer	0.00203	0.00288	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	0.00201	0.0068	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—SFRP2—kidney cancer	0.00198	0.00671	CbGpPWpGaD
Glycerol Phenylbutyrate—Diarrhoea—Paclitaxel—kidney cancer	0.00196	0.00278	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—ITPR2—kidney cancer	0.00194	0.00656	CbGpPWpGaD
Glycerol Phenylbutyrate—Gastrointestinal pain—Capecitabine—kidney cancer	0.00192	0.00273	CcSEcCtD
Glycerol Phenylbutyrate—Dizziness—Paclitaxel—kidney cancer	0.0019	0.00269	CcSEcCtD
Glycerol Phenylbutyrate—Abdominal pain—Capecitabine—kidney cancer	0.00186	0.00264	CcSEcCtD
Glycerol Phenylbutyrate—Malnutrition—Doxorubicin—kidney cancer	0.00186	0.00264	CcSEcCtD
Glycerol Phenylbutyrate—Flatulence—Doxorubicin—kidney cancer	0.00183	0.0026	CcSEcCtD
Glycerol Phenylbutyrate—Vomiting—Paclitaxel—kidney cancer	0.00182	0.00259	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Paclitaxel—kidney cancer	0.00181	0.00257	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Paclitaxel—kidney cancer	0.00181	0.00256	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Paclitaxel—kidney cancer	0.0018	0.00255	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—CRABP1—kidney cancer	0.00175	0.00591	CbGpPWpGaD
Glycerol Phenylbutyrate—Nausea—Paclitaxel—kidney cancer	0.0017	0.00242	CcSEcCtD
Glycerol Phenylbutyrate—Asthenia—Capecitabine—kidney cancer	0.00169	0.0024	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—PSMD7—kidney cancer	0.00163	0.0055	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—ITPR2—kidney cancer	0.00162	0.0055	CbGpPWpGaD
Glycerol Phenylbutyrate—Diarrhoea—Capecitabine—kidney cancer	0.00161	0.00228	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—CASP2—kidney cancer	0.0016	0.00541	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—AKAP13—kidney cancer	0.0016	0.00541	CbGpPWpGaD
Glycerol Phenylbutyrate—Dizziness—Capecitabine—kidney cancer	0.00156	0.00221	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—POMC—kidney cancer	0.0015	0.00507	CbGpPWpGaD
Glycerol Phenylbutyrate—Vomiting—Capecitabine—kidney cancer	0.0015	0.00212	CcSEcCtD
Glycerol Phenylbutyrate—Nervous system disorder—Doxorubicin—kidney cancer	0.00149	0.00211	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Capecitabine—kidney cancer	0.00148	0.00211	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Capecitabine—kidney cancer	0.00148	0.0021	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—GSTT1—kidney cancer	0.00148	0.00501	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—ACHE—kidney cancer	0.00148	0.00501	CbGpPWpGaD
Glycerol Phenylbutyrate—Headache—Capecitabine—kidney cancer	0.00147	0.00209	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—SLC2A1—kidney cancer	0.00147	0.00498	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—GRB7—kidney cancer	0.00146	0.00494	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—JUNB—kidney cancer	0.00146	0.00494	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—SCARB1—kidney cancer	0.0014	0.00475	CbGpPWpGaD
Glycerol Phenylbutyrate—Nausea—Capecitabine—kidney cancer	0.0014	0.00198	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PTGS1—kidney cancer	0.00139	0.0047	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PSMD7—kidney cancer	0.00136	0.00461	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—ITPR2—kidney cancer	0.00136	0.0046	CbGpPWpGaD
Glycerol Phenylbutyrate—Dyspepsia—Doxorubicin—kidney cancer	0.00133	0.00189	CcSEcCtD
Glycerol Phenylbutyrate—Decreased appetite—Doxorubicin—kidney cancer	0.00132	0.00187	CcSEcCtD
Glycerol Phenylbutyrate—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.00131	0.00186	CcSEcCtD
Glycerol Phenylbutyrate—Fatigue—Doxorubicin—kidney cancer	0.00131	0.00186	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—BCHE—kidney cancer	0.00129	0.00437	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—SLC5A5—kidney cancer	0.00127	0.00431	CbGpPWpGaD
Glycerol Phenylbutyrate—Gastrointestinal pain—Doxorubicin—kidney cancer	0.00124	0.00176	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—CTNNA1—kidney cancer	0.00123	0.00417	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—SLC2A1—kidney cancer	0.00123	0.00417	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—HSPB1—kidney cancer	0.00122	0.00414	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—EIF4EBP1—kidney cancer	0.00122	0.00414	CbGpPWpGaD
Glycerol Phenylbutyrate—Abdominal pain—Doxorubicin—kidney cancer	0.0012	0.0017	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	0.00119	0.00404	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—CDKN2B—kidney cancer	0.00119	0.00402	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—ANXA1—kidney cancer	0.00114	0.00385	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—PSMD7—kidney cancer	0.00114	0.00385	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—TSC1—kidney cancer	0.00114	0.00385	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—FLT1—kidney cancer	0.0011	0.00373	CbGpPWpGaD
Glycerol Phenylbutyrate—Asthenia—Doxorubicin—kidney cancer	0.00109	0.00154	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	0.00104	0.00353	CbGpPWpGaD
Glycerol Phenylbutyrate—Diarrhoea—Doxorubicin—kidney cancer	0.00104	0.00147	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—GSTP1—kidney cancer	0.00103	0.00348	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—JUNB—kidney cancer	0.00102	0.00346	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—PAK1—kidney cancer	0.00102	0.00346	CbGpPWpGaD
Glycerol Phenylbutyrate—Dizziness—Doxorubicin—kidney cancer	0.001	0.00142	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—ABCB1—kidney cancer	0.000972	0.00329	CbGpPWpGaD
Glycerol Phenylbutyrate—Vomiting—Doxorubicin—kidney cancer	0.000964	0.00137	CcSEcCtD
Glycerol Phenylbutyrate—Rash—Doxorubicin—kidney cancer	0.000956	0.00136	CcSEcCtD
Glycerol Phenylbutyrate—Dermatitis—Doxorubicin—kidney cancer	0.000955	0.00136	CcSEcCtD
Glycerol Phenylbutyrate—Headache—Doxorubicin—kidney cancer	0.00095	0.00135	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Disease—HIF1A—kidney cancer	0.00095	0.00321	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—TSC2—kidney cancer	0.000947	0.00321	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—GSTM1—kidney cancer	0.000944	0.00319	CbGpPWpGaD
Glycerol Phenylbutyrate—Nausea—Doxorubicin—kidney cancer	0.000901	0.00128	CcSEcCtD
Glycerol Phenylbutyrate—PNLIP—Metabolism—CYP1A1—kidney cancer	0.000895	0.00303	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—APC—kidney cancer	0.000837	0.00283	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—KIT—kidney cancer	0.000837	0.00283	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—IGF2—kidney cancer	0.000836	0.00283	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—CDKN2B—kidney cancer	0.000832	0.00282	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—IGF1R—kidney cancer	0.000808	0.00273	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—BRAF—kidney cancer	0.000787	0.00266	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	0.000735	0.00249	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—POMC—kidney cancer	0.000667	0.00226	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—HIF1A—kidney cancer	0.000665	0.00225	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—TSC2—kidney cancer	0.000663	0.00225	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—RAF1—kidney cancer	0.000657	0.00222	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—ERBB2—kidney cancer	0.00065	0.0022	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—MTOR—kidney cancer	0.000641	0.00217	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—CD4—kidney cancer	0.00064	0.00217	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—KDR—kidney cancer	0.000636	0.00215	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—PTGS2—kidney cancer	0.000635	0.00215	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—CDKN1B—kidney cancer	0.000602	0.00204	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—KIT—kidney cancer	0.000586	0.00198	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—APC—kidney cancer	0.000586	0.00198	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—CTNNB1—kidney cancer	0.000568	0.00192	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—POMC—kidney cancer	0.000558	0.00189	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—PTEN—kidney cancer	0.000554	0.00187	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—BRAF—kidney cancer	0.000551	0.00186	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PTGS2—kidney cancer	0.000532	0.0018	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—MAPK3—kidney cancer	0.000473	0.0016	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PTEN—kidney cancer	0.000464	0.00157	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—MYC—kidney cancer	0.00046	0.00156	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—RAF1—kidney cancer	0.00046	0.00156	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—RELA—kidney cancer	0.000458	0.00155	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—ERBB2—kidney cancer	0.000455	0.00154	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—MAPK1—kidney cancer	0.00045	0.00152	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—MTOR—kidney cancer	0.000449	0.00152	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—KRAS—kidney cancer	0.000425	0.00144	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—CDKN1B—kidney cancer	0.000421	0.00143	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—IL2—kidney cancer	0.000412	0.0014	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—CCND1—kidney cancer	0.000402	0.00136	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—JUN—kidney cancer	0.000401	0.00136	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—CTNNB1—kidney cancer	0.000398	0.00135	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Disease—PIK3CA—kidney cancer	0.000391	0.00132	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—PTEN—kidney cancer	0.000388	0.00131	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—VEGFA—kidney cancer	0.00035	0.00119	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—MAPK3—kidney cancer	0.000332	0.00112	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Metabolism—PIK3CA—kidney cancer	0.000327	0.00111	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—MYC—kidney cancer	0.000322	0.00109	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—MAPK1—kidney cancer	0.000315	0.00107	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—KRAS—kidney cancer	0.000298	0.00101	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—PIK3CA—kidney cancer	0.000274	0.000926	CbGpPWpGaD
Glycerol Phenylbutyrate—PNLIP—Signaling Pathways—TP53—kidney cancer	0.000265	0.000896	CbGpPWpGaD
